Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 5,055 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Drug Interaction
Interventions: ecopipam HCL, Mefenamic acid, Divalproex Sodium ER; Drug
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Anxiety, Cardiovascular Disease
Interventions: Lexapro, Placebo, Supervised Aerobic Exercise; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 40 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: Palbociclib Alone, Palbociclib plus itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Body Weight Changes
Interventions: Meal replacement shake, Multivitamin and mineral capsules, Fish oil with sesame lignans and olive extract softgel, Prebiotic Chewable tablet, Clove Extract and Maqui Berry extract capsule, .Whole Food Blend capsule, Turmeric extract capsule, European White Kidney Bean capsule, Saffron extract capsule, Ubiquinol with Fulvic acid complex softgel, Calcium with Hesperidin and gynostemma extract tablet, Multivitamin and mineral supplement; Dietary Supplement
Lead sponsor: Supplement Formulators, Inc.; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Major Depressive Disorder
Interventions: AZD7268, Escitalopram, Placebo capsules, Placebo tablets; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 17
States / cities: Birmingham, Alabama • Garden Grove, California • San Diego, California + 14 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Nemiralisib, Itraconazole; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Posttraumatic Stress Disorder
Interventions: Omega-3 Fatty Acid, Placebo; Drug
Lead sponsor: Durham VA Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glioblastoma, Astrocytoma, Grade IV
Interventions: XL765 (SAR245409), XL147 (SAR245408); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 1 more

Conditions: Laparoscopic Cholecystectomy
Interventions: 2 capsules Oral Tylenol 2000 mg and IV "salt water", IV tylenol 1000mg and 2 oral capsule "sugar pills"; Drug
Lead sponsor: Defense and Veterans Center for Integrative Pain Management; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Fort Bragg, North Carolina

Conditions: Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Pleiotropic Pathway Modifier, Glioblastoma, Lymphoma, Primary Central Nervous System Lymphoma
Interventions: CC-122; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 17
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 13 more

Conditions: Pompe Disease
Interventions: Albuterol, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Bipolar Disorder
Interventions: Valacyclovir, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
Interventions: EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Placebo, Antipsychotic therapy; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Wichita, Kansas

Conditions: Rheumatoid Arthritis
Interventions: Lovastatin, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more

Conditions: ALK-activated Tumors
Interventions: Ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Months to 17 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Cincinnati, Ohio + 2 more

Conditions: Castration-Resistant Prostatic Cancer
Interventions: Niraparib, Abiraterone Acetate, Prednisone, Placebo, New Formulation of Niraparib and Abiraterone Acetate (AA); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 765 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 47
States / cities: Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more

Conditions: Insulin Resistance, Hyperinsulinemia, Dyslipidemias
Interventions: Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), Placebo (microcrystalline cellulose), 2 capsules, FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage, BOOST Plus nutritional beverage; Drug · Device · Diagnostic Test + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: Midazolam, Repaglinide, TAK-279; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Oral Sedation and Cervical Dilator Pain
Interventions: Oxycodone and Lorazepam (Active Comparator), Placebo Comparator; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Dasatinib, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • Cleveland, Ohio • Seattle, Washington

Conditions: Non-alcoholic Steatohepatitis (NASH)
Interventions: ECC4703, Placebo; Drug
Lead sponsor: Eccogene; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Healthy Volunteers
Interventions: Avacopan, Simvastatin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver
Interventions: Omega-3-acid ethyl esters, Placebo; Drug
Lead sponsor: Boston University; Other
Eligibility: 13 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Cancer
Interventions: Mocetinostat - 50 mg, Mocetinostat - 70 mg, Mocetinostat - 90 mg, Mocetinostat - Recommended Phase 2 Dose (70 mg), Durvalumab - 1500 mg; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 15
States / cities: Mobile, Alabama • Los Angeles, California • Pensacola, Florida + 12 more

Search by objective public record fields.

Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite

Exercise and Pharmacotherapy for Anxiety in Cardiac Patients

Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib

Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain

AZD7268 Safety and Tolerability Study

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib

Omega-3 Fatty Acids and Post Traumatic Stress Disorder (PTSD)

Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection

Comparing Effectiveness of IV vs Oral Acetaminophen Given Perioperatively for Lap Choles for Pain Control,

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease

Research Study of Bipolar Mood Symptoms and Cognitive Problems

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

Effect of Alpelisib in Healthy Volunteers

A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

Oral Sedation During Cervical Dilator Placement

Dasatinib for HIV-1 Reservoir Reduction

FTIH of ECC4703 in Healthy Volunteers

Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin

Study of Fish Oil to Reduce ALT Levels in Adolescents

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC